Malin Corporation PLC Kymab Rule 135 Press Release (8455Y)

TIDM0Y71

RNS Number : 8455Y

Malin Corporation PLC

13 May 2019

Malin Corporation plc

Kymab submits confidential draft registration statement for proposed IPO

Dublin-Ireland, 13 May 2019: Malin Corporation plc's (Euronext Growth Dublin:MLC) ("Malin") investee Priority Asset, Kymab Group Limited ("Kymab"), today announced that it has previously confidentially submitted a draft registration statement on Form F-1 to the US Securities and Exchange Commission (the "SEC") relating to the proposed initial public offering of American Depositary Shares, each of which will represent one or a number of its ordinary shares.

The number of shares to be offered and the price range for the proposed offering have not yet been determined. The initial public offering is expected to commence after the SEC completes its review process, subject to market and other conditions.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the US Securities Act of 1933, as amended (the "Securities Act"). This announcement is being issued in accordance with Rule 135 under the Securities Act.

Malin owns approximately 8% of Kymab.

A copy of Kymab's press release is available to view here:

https://www.kymab.com/news-and-events/news/2019/may/13/kymab-rule-135/

ENDS

For further information please contact:

Malin

Jessica Bergin, Director of Investor Relations & External Reporting

Tel: +353 (0)1 901 5700

investorrelations@malinplc.com

Davy Corporate Finance (Euronext Growth Adviser)

Brian Garrahy / Daragh O'Reilly

Tel: +353 1 679 6363

Consilium Strategic Communications

Mary-Jane Elliott / Jessica Hodgson

Tel: +44 (0)20 3709 5700

malin@consilium-comms.com

Powerscourt (Irish media enquiries)

Jack Hickey

Tel: +353 83 448 8339

malin@powerscourt-group.com

About Malin Corporation plc

Malin (Euronext Growth Dublin:MLC) is a company investing in and supporting highly innovative life sciences companies developing exceptional science and technology to deliver transformative outcomes for patients and create significant value for shareholders. Its purpose is to create shareholder value through the application of long-term capital and strategic support to its investee companies to enable them to reach their value potential. Malin is headquartered and domiciled in Ireland and listed on the Euronext Growth Dublin. For more information visit www.malinplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCSFAFFDFUSEDI

(END) Dow Jones Newswires

May 13, 2019 07:42 ET (11:42 GMT)

Malin (LSE:0Y71)
Historical Stock Chart
From Aug 2024 to Sep 2024